CTAG1B (Cancer/testis antigen 1B)

Based on the study findings, an increase antigen-specific immune response by vaccinating the patient with a tumor-associated peptide in combination with anti-PD-1 antibody would be advantageous in HNSCC. Efforts into finding and developing new combination therapies should be further advanced.

P1/2, N=24, Not yet recruiting, University of Chicago

Our findings apply to recently approved treatments, such as PD-1 and vascular endothelial growth factor A (VEGF-A) blockade, but not to chemotherapy alone, suggesting broad relevance to individuals treated with immunotherapy. Collectively, our results demonstrate that PD-1 blockade induces tumor-specific IgG1+ plasma cell responses that complement cellular immunity and contribute to clinical benefit, underscoring a coordinated humoral-cellular axis in effective antitumor immunity.

A secondary chemical screen in patient-derived GBM cultures identified putative kinase targets of immune evasion phenotypes (e.g., EPHA2 and PDGFRA), whose inhibition leads to the blockade of evasive programs and enhances T cell-mediated GBM killing. Together, this workflow provides a scalable blueprint for comprehensive charting of the genetic control of tumor-immune interactions.

P1, N=20, Suspended, University of Southern California | Recruiting --> Suspended

P3, N=5, Recruiting, Takara Bio Inc. | Not yet recruiting --> Recruiting

Clinical outcomes correlated with peripheral expansion of functional TAA-targeted T cell clones and treatment-emergent antigen spreading. Thus, further investigation of this approach, either as a single agent or combined with other complementary modalities, is warranted (ClinicalTrials.gov identifier: NCT03192462 ).

SD-DC-NY effectively primes cytotoxic T-lymphocytes and enhances antitumor activity against NY-ESO-1-positive MM cells, supporting NY-ESO-1 as an immunotherapeutic target and highlighting SD-DC-NY as a promising platform for MM immunotherapy.

P1, N=22, Active, not recruiting, University Health Network, Toronto | Trial completion date: Sep 2025 --> Nov 2026 | Trial primary completion date: Sep 2025 --> Nov 2026

Furthermore, we propose an innovative four-part mRNA vaccine approach to balance therapeutic effectiveness with clinical practicalities. Both vaccine formulations showed intense immune stimulation in silico, indicating their potential as promising candidates for immunotherapy against TNBC, which will require further experimental exploration.

P2, N=6, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Nov 2025 --> Nov 2026

The biovaccine improved the immune infiltrating state of the tumour microenvironment and metastasis niche, inhibited tumor progression and prevented recurrence. It is demonstrated that FOL-M@NLP serves as a potent and safe antitumour platform that enhances antigen peptide delivery and facilitates the advancement of therapeutic biological vaccine platforms.